NASDAQ:ACCD Accolade (ACCD) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free ACCD Stock Alerts $7.48 +0.15 (+2.05%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$7.18▼$7.4950-Day Range$7.12▼$10.4852-Week Range$6.33▼$15.36Volume535,827 shsAverage Volume768,424 shsMarket Capitalization$586.13 millionP/E RatioN/ADividend YieldN/APrice Target$14.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Accolade alerts: Email Address Accolade MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside89.1% Upside$14.14 Price TargetShort InterestBearish4.76% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.28Based on 8 Articles This WeekInsider TradingSelling Shares$60,467 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.24) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 starsBusiness Services Sector30th out of 310 stocksBusiness Services, Not Elsewhere Classified Industry14th out of 91 stocks 4.4 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAccolade has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Accolade's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.76% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Accolade has recently increased by 18.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.89. Previous Next 2.4 News and Social Media Coverage News SentimentAccolade has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Accolade this week, compared to 3 articles on an average week.Search Interest5 people have searched for ACCD on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,467.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Accolade's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.24) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Accolade's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Accolade Stock (NASDAQ:ACCD)Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesMay 15, 2024 | americanbankingnews.comShort Interest in Accolade, Inc. (NASDAQ:ACCD) Rises By 18.8%May 10, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMay 10, 2024 | americanbankingnews.comAccolade (NASDAQ:ACCD) PT Lowered to $13.00April 30, 2024 | finance.yahoo.comAccolade, Inc. (NASDAQ:ACCD) Q4 2024 Earnings Call TranscriptApril 27, 2024 | benzinga.comAccolade Stock (NASDAQ:ACCD), Analyst Ratings, Price Targets, PredictionsApril 26, 2024 | markets.businessinsider.comAccolade’s Hold Rating Affirmed Amid Conservative Outlook and Adjusted Financial EstimatesApril 26, 2024 | markets.businessinsider.comAccolade’s Hold Rating Affirmed Amid Revenue Growth Uncertainty and Earnings VolatilityApril 26, 2024 | finance.yahoo.comAccolade Inc (ACCD) Q4 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic ...April 25, 2024 | sfgate.comAccolade: Fiscal Q4 Earnings SnapshotApril 25, 2024 | msn.comACCD Stock Earnings: Accolade Misses EPS, Beats Revenue for Q4 2024April 25, 2024 | finance.yahoo.comAccolade Inc (ACCD) Surpasses Revenue Expectations and Narrows Losses in Fiscal Q4 and Full ...April 25, 2024 | globenewswire.comAccolade Announces Results for Fiscal Fourth Quarter and Full Year 2024April 24, 2024 | investing.comStifel cuts Accolade stock price target to $13, maintains buy ratingApril 23, 2024 | finance.yahoo.comAccolade, Inc. (ACCD)April 22, 2024 | benzinga.comAlphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For MondayApril 21, 2024 | investing.comAccolade CEO Rajeev Singh sells $3.1k in stockApril 18, 2024 | morningstar.comAccolade Inc Ordinary SharesApril 14, 2024 | uk.investing.comAccolade CFO exercises options, sells shares for tax obligationsApril 5, 2024 | seekingalpha.comAccolade: Staying Bullish On Favorable DevelopmentsApril 3, 2024 | finance.yahoo.comAccolade to Announce Fiscal Fourth Quarter 2024 Financial ResultsApril 1, 2024 | finance.yahoo.comRecent uptick might appease Accolade, Inc. (NASDAQ:ACCD) institutional owners after losing 24% over the past yearMarch 20, 2024 | prnewswire.comAccolade Wins 2024 Artificial Intelligence Excellence AwardMarch 19, 2024 | businesswire.comNational Accolade Bestowed on Arkansas-Based Provider: ‘Best Rural High Speeds'March 19, 2024 | prnewswire.comAccolade Promotes Kelsi McDonald Harris to Chief People OfficerMarch 17, 2024 | finance.yahoo.comACCD Apr 2024 10.000 callSee More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/19/2024Next Earnings (Estimated)7/04/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,400Year FoundedN/APrice Target and Rating Average Stock Price Target$14.14 High Stock Price Target$18.00 Low Stock Price Target$10.00 Potential Upside/Downside+89.1%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,810,000.00 Net Margins-24.09% Pretax Margin-23.79% Return on Equity-22.53% Return on Assets-12.08% Debt Debt-to-Equity Ratio0.47 Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual Sales$414.29 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.30Miscellaneous Outstanding Shares78,360,000Free Float71,853,000Market Cap$586.13 million OptionableOptionable Beta2.15 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 56)Chairman of the Board & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 55)President Comp: $582.63kMr. Stephen H. Barnes CPA (Age 52)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSenior Vice President of OperationsMr. Colin McHugh (Age 45)Chief Accounting Officer Mr. Todd FriedmanSenior Vice President of Investor RelationsMr. Richard Eskew (Age 49)Executive VP, General Counsel, CCO & Secretary Ms. Kelsi McDonald HarrisChief People Officer & Senior Vice PresidentMr. Drew GarnerExecutive Vice President of EngineeringDr. Shantanu Nundy M.B.A.M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsLiquidity ServicesNASDAQ:LQDTInternational Money ExpressNASDAQ:IMXISezzleNASDAQ:SEZLViadNYSE:VVIResources ConnectionNASDAQ:RGPView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 2,000 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 2,621 shares on 5/16/2024Ownership: 0.089%Bellevue Group AGBought 297,110 shares on 5/15/2024Ownership: 6.131%Lazard Asset Management LLCSold 8,860 shares on 5/15/2024Ownership: 0.126%Price T Rowe Associates Inc. MDBought 2,586 shares on 5/15/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions ACCD Stock Analysis - Frequently Asked Questions Should I buy or sell Accolade stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price target for 2024? 17 brokers have issued 12 month price objectives for Accolade's stock. Their ACCD share price targets range from $10.00 to $18.00. On average, they anticipate the company's share price to reach $14.14 in the next twelve months. This suggests a possible upside of 89.1% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2024? Accolade's stock was trading at $12.01 at the beginning of the year. Since then, ACCD stock has decreased by 37.7% and is now trading at $7.48. View the best growth stocks for 2024 here. When is Accolade's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ACCD earnings forecast. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings data on Thursday, April, 25th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The company earned $124.80 million during the quarter, compared to the consensus estimate of $123.91 million. Accolade had a negative net margin of 24.09% and a negative trailing twelve-month return on equity of 22.53%. The firm's quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.42) earnings per share. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS) and Fidelity Digital Health ETF (FDHT).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Accolade issued on next quarter's earnings? Accolade updated its first quarter 2025 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $103.0 million-$106.0 million, compared to the consensus revenue estimate of $110.9 million. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? Accolade (ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. Who are Accolade's major shareholders? Accolade's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.90%), Bellevue Group AG (6.13%), Sumitomo Mitsui Trust Holdings Inc. (2.19%), Nikko Asset Management Americas Inc. (2.17%), Fairman Group LLC (1.47%) and Swiss National Bank (0.18%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACCD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.